SEARCH

SEARCH BY CITATION

References

  • 1
    Kobayashi M, Tanaka E, Oguchi H, Hora K, Kiyosawa K. Prospective follow-up study of hepatitis C virus infection in patients undergoing maintenance haemodialysis: comparison among haemodialysis units. J. Gastroenterol. Hepatol. 1998; 13: 6049.
  • 2
    Furusyo N, Hayashi J, Kakuda K et al. Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. Am. J. Gastroenterol. 2001; 96: 1592600.
    Direct Link:
  • 3
    Kumagai J, Komiya Y, Tanaka J et al. Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003. J. Med. Virol. 2005; 76: 498502.
  • 4
    Liu CH, Liang CC, Liu CJ et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin. Infect. Dis. 2010; 51: 5419.
  • 5
    Fabrizi F, Martin P, Dixit V et al. Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients. Am. J. Nephrol. 1999; 19: 3838.
  • 6
    Fabrizi F, de Vecchi AF, Como G, Lunghi G, Martin P. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment. Pharmacol. Ther. 2005; 21: 8619.
  • 7
    Schneeberger PM, Keur I, van Loon AM et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J. Infect. Dis. 2000; 182: 12919.
  • 8
    Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney. Int. 1993; 44: 13226.
  • 9
    Izopet J, Sandres-Sauné K, Kamar N et al. Incidence of HCV infection in French hemodialysis units: a prospective study. J. Med. Virol. 2005; 77: 706.
  • 10
    Lombardi M, Cerrai T, Geatti S et al. Results of a national epidemiological investigation on HCV infection among dialysis patients (survey by the Italian branch of EDTNA/ERCA). J. Nephrol. 1999; 12: 3227.
  • 11
    Petrosillo N, Gilli P, Serraino D et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am. J. Kidney. Dis. 2001; 37: 100410.
  • 12
    Sypsa V, Psichogiou M, Katsoulidou A et al. Incidence and patterns of hepatitis C virus seroconversion in a cohort of hemodialysis patients. Am. J. Kidney. Dis. 2005; 45: 33443.
  • 13
    Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Aljama P. Natural history of acute HCV infection in hemodialysis patients. Clin. Nephrol. 2002; 58: 14350.
  • 14
    Moreira R, Pinho JR, Fares J et al. Prospective study of hepatitis C virus infection in hemodialysis patients by monthly analysis of HCV RNA and antibodies. Can. J. Microbiol. 2003; 49: 5037.
  • 15
    Santos MA, Souto FJ. Infection by the hepatitis C virus in chronic renal failure patients undergoing hemodialysis in Mato Grosso state, central Brazil: a cohort study. BMC. Public. Health. 2007; 7: 32.
  • 16
    Hmaied F, Ben Mamou M, Saune-Sandres K et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J. Med. Virol. 2006; 78: 18591.
  • 17
    Ben Othman S, Bouzgarrou N, Achour A, Bourlet T, Pozzetto B, Trabelsi A. High prevalence and incidence of hepatitis C virus infections among dialysis patients in the East-Centre of Tunisia. Pathol. Biol. 2004; 52: 3237.
  • 18
    Fissell RB, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney. Int. 2004; 65: 233542.
  • 19
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet. Infect. Dis. 2005; 5: 55867.
  • 20
    Okuda K, Hayashi H, Yokozeki K, Kobayashi S, Kashima T, Irie Y. Acute hepatitis C among renal failure patients on chronic haemodialysis. J. Gastroenterol. Hepatol. 1998; 13: 627.
  • 21
    Lemos LB, Perez RM, Matos CA et al. Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis. J. Clin. Gastroenterol. 2008; 42: 20811.
  • 22
    Iwasaki Y, Esumi M, Hosokawa N, Yanai M, Kawano K. Occasional infection of hepatitis C virus occurring in haemodialysis units identified by serial monitoring of the virus infection. J. Hosp. Infect. 2000; 45: 5461.
  • 23
    Kao JH, Huang CH, Chen W et al. GB virus C infection in hemodialysis patients: molecular evidence for nosocomial transmission. J. Infect. Dis. 1999; 180: 1914.
  • 24
    Dai CY, Yu ML, Chuang WL et al. Epidemiology and clinical significance of chronic hepatitis-related viruses infection in hemodialysis patients from Taiwan. Nephron 2002; 90: 14853.
  • 25
    Sivapalasingam S, Malak SF, Sullivan JF, Lorch J, Sepkowitz KA. High prevalence of hepatitis C infection among patients receiving hemodialysis at an urban dialysis center. Infect. Control. Hosp. Epidemiol. 2002; 23: 31924.
  • 26
    Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Hepatitis C virus and death risk in hemodialysis patients. J. Am. Soc. Nephrol. 2007; 18: 158493.
  • 27
    Méndez-Sánchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J. Clin. Microbiol. 2004; 42: 43212.
  • 28
    Jadoul M, Poignet JL, Geddes C et al. HCV Collaborative Group. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol. Dial. Transplant. 2004; 19: 9049.
  • 29
    Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J. Med. Virol. 2000; 61: 4451.
  • 30
    Da Porto A, Adami A, Susanna F et al. Hepatitis C virus in dialysis units: a multicenter study. Nephron 1992; 61: 30910.
  • 31
    Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE, PHV Study Group. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut 2002; 51: 42933.
  • 32
    Covic A, Iancu L, Apetrei C et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol. Dial. Transplant. 1999; 14: 405.
  • 33
    Yoshida CF, Takahashi C, Gaspar AM, Schatzmayr HG, Ruzany F. Hepatitis C virus in chronic hemodialysis patients with non-A, non-B hepatitis. Nephron 1992; 60: 1503.
  • 34
    Mahmoud IM, Sobh MA, Amer GM et al. A prospective study of hepatitis C viremia in renal allograft recipients. Am. J. Nephrol. 1999; 19: 57685.
  • 35
    Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM. Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi. Med. J. 2002; 23: 135660.
  • 36
    Diouf ML, Diouf B, Niang A et al. Prevalence of hepatitis B and C viruses in a chronic hemodialysis center in Dakar. Dakar. Med. 2000; 45: 14.
  • 37
    Fabrizi F, Messa P, Martin P. Transmission of hepatitis C virus infection in hemodialysis: current concepts. Int. J. Artif. Organs. 2008; 31: 100416.
  • 38
    dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol. Dial. Transplant. 1996; 11: 201722.
  • 39
    Simon N, Couroucé AM, Lemarrec N, Trépo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney. Int. 1994; 46: 50411.
  • 40
    Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney. Int. 1998; 53: 10225.
  • 41
    Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. J. Infec. Dis. 1993; 158: 13438.
  • 42
    Pereira BJ, Natov SN, Bouthot BA et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney. Int. 1998; 53: 137481.
  • 43
    Stehman-Breen CO, Emerson S, Gretch D, Johnson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am. J. Kidney. Dis. 1998; 32: 62934.
  • 44
    Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J. Am. Soc. Nephrol. 2000; 11: 1896902.
  • 45
    Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol. Dial. Transplant. 2001; 16: 166974.
  • 46
    Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol. Dial. Transplant. 2005; 20: 16629.
  • 47
    Di Napoli A, Pezzotti P, Di Lallo D, Petrosillo N, Trivelloni C, Di Giulio S, Lazio Dialysis Registry. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am. J. Kidney. Dis. 2006; 48: 62937.
  • 48
    Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J. Viral. Hepat. 2007; 14: 697703.
  • 49
    Butt AA, Skanderson M, McGinnis KA et al. Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J. Viral. Hepat. 2007; 14: 68896.
  • 50
    Wang SM, Liu JH, Chou CY, Huang CC, Shih CM, Chen W. Mortality in hepatitis C-positive patients treated with peritoneal dialysis. Perit. Dial. Int. 2008; 28: 1837.
  • 51
    Butt AA, Khan UA, Skanderson M. Comorbidities and their impact on mortality in HCV and HCV–HIV-coinfected persons on dialysis. J. Clin. Gastroenterol. 2008; 42: 105459.
  • 52
    Fabrizi F, Messa P, Martin P. Health-related quality of life in dialysis patients with HCV infection. Int. J. Artif. Organs. 2009; 32: 47381.
  • 53
    Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799805.
  • 54
    Stehman-Breen CO, Psaty BM, Emerson S et al. Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients. Transplantation 1997; 64: 2816.
  • 55
    Hanafusa T, Ichikawa Y, Kishikawa H et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 4716.
  • 56
    Legendre C, Garrigue V, Le Bihan C et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 66770.
  • 57
    Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 25763.
  • 58
    Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 74550.
  • 59
    Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am. J. Kidney. Dis. 2004; 43: 1319.
  • 60
    Manga Sahin G, Sahin S, Kantarci G, Ergin H. Impact of hepatitis C virus infection on patient and graft survival in kidney transplantation. Transplant. Proc. 2006; 38: 499501.
  • 61
    Vosnides GG. Hepatitis C in renal transplantation. Kidney. Int. 1997; 52: 84361.
  • 62
    Izopet J, Rostaing L, Sandres K et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J. Infect. Dis. 2000; 181: 8528.
  • 63
    Zylberberg H, Nalpas B, Carnot F et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol. Dial. Transplant. 2002; 17: 12933.
  • 64
    Toz H, Ok E, Yilmaz F et al. Clinicopathological features of hepatitis C virus infection in dialysis and renal transplantation. J. Nephrol. 2007; 15: 30812.
  • 65
    Kalantar-Zadeh K, Miller LG, Daar ES. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. Am. J. Kidney. Dis. 2005; 46: 290300.
  • 66
    Dalekos GN, Boumba DS, Katopodis K et al. Absence of HCV viraemia in anti-HCV-negative haemodialysis patients. Nephrol. Dial. Transplant. 1998; 13: 18046.
  • 67
    Schneeberger PM, Keur I, van der Vliet W et al. Hepatitis C virus infections in dialysis centers in the Netherlands: a national survey by serological and molecular methods. J. Clin. Microbiol. 1998; 36: 17115.
  • 68
    Furusyo N, Hayashi J, Ariyama I et al. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am. J. Gastroenterol. 2000; 95: 4906.
    Direct Link:
  • 69
    Fabrizi F, Martin P, Dixit V et al. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am. J. Kidney. Dis. 2000; 35: 1229.
  • 70
    Kaiser T, Damerow HC, Tenckhoff S et al. Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. J. Med. Virol. 2008; 80: 1195201.
  • 71
    Mizuno M, Higuchi T, Yanai M, Kanmatsuse K, Esumi M. Dialysis-membrane-dependent reduction and adsorption of circulating hepatitis C virus during hemodialysis. Nephron 2002; 91: 23542.
  • 72
    Badalamenti S, Catania A, Lunghi G et al. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? Am. J. Kidney. Dis. 2003; 42: 14350.
  • 73
    Fabrizi F, Lunghi G, Guarnori I et al. Hepatitis C virus genotypes in chronic dialysis patients. Nephrol. Dial. Transplant. 1996; 11: 67983.
  • 74
    Yu ML, Wang LY, Chuang WL et al. Serotyping and genotyping of hepatitis C virus in Taiwanese patients with type C chronic liver disease and uraemic patients on maintenance haemodialysis. J. Gastroenterol. Hepatol. 2000; 15: 7927.
  • 75
    Selcuk H, Kanbay M, Korkmaz M et al. Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment. Dig. Dis. Sci. 2006; 51: 14205.
  • 76
    de Paula Farah K, Carmo RA, Antunes CM et al. Hepatitis C, HCV genotypes and hepatic siderosis in patients with chronic renal failure on haemodialysis in Brazil. Nephrol. Dial. Transplant. 2007; 22: 202731.
  • 77
    Fabrizi F, Lunghi G, Andrulli S et al. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol. Dial. Transplant. 1997; 12: 13948.
  • 78
    Espinosa M, Martin-Malo A, Alvarez de Lara MA, Soriano S, Aljama P. High ALT levels predict viremia in anti-HCV-positive HD patients if a modified normal range of ALT is applied. Clin. Nephrol. 2000; 54: 1516.
  • 79
    Hung KY, Lee KC, Yen CJ, Wu KD, Tsai TJ, Chen WY. Revised cutoff values of serum aminotransferase in detecting viral hepatitis among CAPD patients: experience from Taiwan, en endemic area for hepatitis. B. Nephrol. Dial. Transplant. 1997; 12: 1803.
  • 80
    Lopes EPA, Gouveia EC, Albuquerque ACC et al. Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia. J. Clin. Virol. 2006; 35: 298302.
  • 81
    Sterling RK, Sanyal AJ, Luketic VA et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am. J. Gastroenterol. 1999; 94: 357682.
    Direct Link:
  • 82
    Cotler SJ, Diaz G, Gundlapalli S et al. Characteristics of hepatitis C in renal transplant candidates. J. Clin. Gastroenterol. 2002; 35: 1915.
  • 83
    Trevizoli JE, de Paula Menezes R, Ribeiro Velasco LF et al. Hepatitis C is less aggressive in hemodialysis patients than in nonuremic patients. Clin. J. Am. Soc. Nephrol. 2008; 3: 138590.
  • 84
    Becker VR, Badiani RG, Lemos LB et al. Factors associated with the progression of hepatic fibrosis in end-stage kidney disease patients with hepatitis C virus infection. Eur. J. Gastroenterol. Hepatol. 2009; 21: 13959.
  • 85
    Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 344: 495500.
  • 86
    Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49: 101744.
  • 87
    Ozdoğan M, Ozgür O, Boyacioğlu S et al. Percutaneous liver biopsy complications in patients with chronic renal failure. Nephron 2006; 74: 4423.
  • 88
    Pawa S, Ehrinpreis M, Mutchnick M, Janisse J, Dhar R, Siddiqui FA. Percutaneous liver biopsy is safe in chronic hepatitis C patients with end-stage renal disease. Clin. Gastroenterol. Hepatol. 2007; 5: 131620.
  • 89
    Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 144957.
  • 90
    Schiavon LL, Schiavon JL, Filho RJ et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007; 46: 30714.
  • 91
    Liu CH, Liang CC, Liu CJ et al. The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C. Kidney. Int. 2010; 78: 1039.
  • 92
    Liu CH, Liang CC, Liu CJ et al. Transient elastography for the assessment of hepatic fibrosis in hemodialysis patients with chronic hepatitis C. Hepatol. Int. 2010; 4: 23.
  • 93
    Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 94
    Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 77889.
  • 95
    Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med. 2001; 345: 14527.
  • 96
    Nomura H, Sou S, Tanimoto H et al. Short-term interferon alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39: 12139.
  • 97
    Süleymanlar I, Sezer T, Işitan F, Yakupoglu G, Süleymanlar G. Efficacy of interferon alpha in acute hepatitis C in patients on chronic hemodialysis. Nephron 1998; 79: 3534.
  • 98
    Gürsoy M, Gür G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J. Viral. Hepat. 2001; 8: 707.
  • 99
    Urbánek P, Tesar V, Procházková-Francisci E, Lachmanová J, Marecek Z, Svobodník A. Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-alpha. Treatment of hepatitis C. Blood. Purif. 2004; 22: 34450.
  • 100
    Al-Harbi AS, Malik GH, Subaity Y, Mansy H, Abutaleb N. Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi. J. Kidney. Dis. Transplant. 2005; 16: 2937.
  • 101
    Rocha CM, Perez RM, Narciso JL et al. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance. Eur. J. Gastroenterol. Hepatol. 2007; 19: 11923.
  • 102
    Engel M, Malta FM, Gomes MM et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the southwest Parana State, Brazil. BMC. Public. Health. 2007; 7: 50.
  • 103
    Kamal SM, Moustafa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43: 92331.
  • 104
    Santantonio T, Fasano M, Sinisi E et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol. 2005; 42: 32933.
  • 105
    Koenig P, Vogel W, Umlauft F et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney. Int. 1994; 45: 15079.
  • 106
    Pol S, Thiers V, Carnot F et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney. Int. 1995; 47: 14128.
  • 107
    Raptopoulou-Gigi M, Spaia S, Garifallos A et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol. Dial. Transplant. 1995; 10: 18347.
  • 108
    Fernández JL, Rendo P, del Pino N, Viola L. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection. J. Viral. Hepat. 1997; 4: 1139.
  • 109
    Izopet J, Rostaing L, Moussion F et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J. Infect. Dis. 1997; 176: 16147.
  • 110
    Chan TM, Wu PC, Lau JY, Lok AS, Lai CL, Cheng IK. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol. Dial. Transplant. 1997; 12: 14149.
  • 111
    Uchihara M, Izumi N, Sakai Y et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998; 80: 516.
  • 112
    Benci A, Caremani M, Menchetti D, Sasdelli M, Giusti PB. Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C. Curr. Med. Res. Opin. 1998; 14: 1414.
  • 113
    Djordjević V, Kostić S, Stefanović V. Treatment of chronic hepatitis C with interferon alpha in patients on maintenance hemodialysis. Nephron 1998; 79: 22931.
  • 114
    Boran M, Cetin S. The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy. Nephron 1999; 82: 226.
  • 115
    Campistol JM, Esforzado N, Martínez J et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol. Dial. Transplant. 1999; 14: 27049.
  • 116
    Huraib S, Tanimu D, Romeh SA et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am. J. Kidney. Dis. 1999; 34: 5560.
  • 117
    Hanrotel C, Toupance O, Lavaud S et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001; 88: 1206.
  • 118
    Casanovas-Taltavull T, Baliellas C, Benasco C et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am. J. Gastroenterol. 2001; 96: 11707.
  • 119
    Degos F, Pol S, Chaix ML et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol. Dial. Transplant. 2001; 16: 101723.
  • 120
    Espinosa M, Rodriguez M, Martin-Malo A et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin. Nephrol. 2001; 55: 2206.
  • 121
    Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J. Am. Soc. Nephrol. 2003; 14: 20928.
  • 122
    Ozdemir FN, Akcay A, Sezer S et al. A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren. Fail. 2004; 26: 5838.
  • 123
    Mahmoud IM, Sobh MA, El-Habashi AF et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron. Clin. Pract. 2005; 100: c1339.
  • 124
    Rivera M, Gentil MA, Sayago M et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant. Proc. 2005; 37: 14245.
  • 125
    Buargub M, El Huni S, Tagdi M. Tolerance and efficacy of interferon-alpha in hemodialysis patients in Tripoli. Saudi. J. Kidney. Dis. Transpl. 2006; 17: 33843.
  • 126
    Rocha CM, Perez RM, Ferreira AP et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver. Int. 2006; 26: 30510.
  • 127
    Grgurević I, Vince A, Buljevac M et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron. Clin. Pract. 2006; 103: c811.
  • 128
    Liu CH, Liang CC, Lin JW et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57: 52530.
  • 129
    Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment. Pharmacol. Ther. 2003; 18: 107181.
  • 130
    Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am. J. Gastroenterol. 2003; 98: 16105.
    Direct Link:
  • 131
    Fabrizi F, Dixit V, Messa P, Martin P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J. Viral. Hepat. 2008; 15: 7988.
  • 132
    Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am. J. Kidney. Dis. 2008; 51: 26377.
  • 133
    Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J. Am. Soc. Nephrol. 1998; 9: 23448.
  • 134
    Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 2004; 20: 1234.
  • 135
    Teta D, Lüscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol. Dial. Transplant. 2005; 20: 9913.
  • 136
    Sporea I, Popescu A, Sirli R et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World. J. Gastroenterol. 2006; 12: 41914.
  • 137
    Kokoglu OF, Uçmak H, Hosoglu S et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2006; 21: 57580.
  • 138
    Covic A, Maftei ID, Mardare NG et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J. Nephrol. 2006; 19: 794801.
  • 139
    Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol. Dial. Transplant. 2006; 21: 43743.
  • 140
    Casanovas-Taltavull T, Baliellas C, Llobet M et al. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant. Proc. 2007; 39: 21257.
  • 141
    Amarapurkar DN, Patel ND, Kirpalani AL. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis. Trop. Gastroenterol. 2007; 28: 168.
  • 142
    Sikole A, Dzekova P, Selja N et al. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy. Ren. Fail. 2007; 29: 9616.
  • 143
    Chan TM, Ho SK, Tang CS et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology 2007; 12: 117.
  • 144
    Espinosa M, Arenas MD, Aumente MD et al. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients. Clin. Nephrol. 2007; 67: 36673.
  • 145
    Ayaz C, Celen MK, Yuce UN, Geyik MF. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World. J. Gastroenterol. 2008; 14: 2559.
  • 146
    Akhan SC, Kalender B, Ruzgar M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection. 2008; 36: 3414.
  • 147
    Kose S, Gurkan A, Akman F, Kelesoglu M, Uner U. Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey. J. Gastroenterol. 2009; 44: 3538.
  • 148
    Tan SS, Abu Hassan MR, Abdullah A, Ooi BP, Korompis T, Merican MI. Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C. J. Viral. Hepat. 2010; 17: 4108.
  • 149
    Fabrizi F, Dixit V, Messa P, Martin P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J. Med. Virol. 2010; 82: 76875.
  • 150
    Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon for hepatitis C virus in hemodialysis—an individual patient meta-analysis of factors associated with sustained virological response. Clin. J. Am. Soc. Nephrol. 2009; 4: 144958.
  • 151
    Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000; 343: 166672.
  • 152
    Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 153
    Gupta SK, Pittenger AL, Swan SK et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J. Clin. Pharmacol. 2002; 42: 110915.
  • 154
    Lamb TW, Marks IM, Wynohradnyk L, Modi MW, Preston RA, Pappas SC. 40 kDa peginterferon alfa-2a (Pegasys@) can be administered safety in patients with end-stage renal disease. Hepatology 2001; 34: 326A.
  • 155
    McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 148592.
  • 156
    Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352: 142632.
  • 157
    Bruchfeld A, Ståhle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. J. Viral. Hepat. 2001; 8: 28792.
  • 158
    Tan AC, Brouwer JT, Glue P et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol. Dial. Transplant. 2001; 16: 1935.
  • 159
    Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant. Proc. 2004; 36: 18314.
  • 160
    Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J. Viral. Hepat. 2006; 13: 31621.
  • 161
    Rendina M, Schena A, Castellaneta NM et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J. Hepatol. 2007; 46: 76874.
  • 162
    Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int. J. Artif. Organs. 2008; 31: 295302.
  • 163
    van Leusen R, Adang RP, de Vries RA et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol. Dial. Transplant. 2008; 23: 7215.
  • 164
    Hakim W, Sheikh S, Inayat I et al. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J. Clin. Gastroenterol. 2009; 43: 47781.
  • 165
    Liu CH, Liang CC, Liu CJ et al. Pegylated interferon alfa-2a plus low dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 2009; 58: 3146.
  • 166
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358: 95865.
  • 167
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 97582.
  • 168
    Fabrizi F, Lunghi G, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment. Pharmacol. Ther. 2006; 24: 141322.
  • 169
    Magnone M, Holley JL, Shapiro R et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 106870.
  • 170
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 5126.
  • 171
    Kamar N, Sandres-Saune K, Selves J et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am. J. Kidney. Dis. 2003; 42: 18492.
  • 172
    Fontaine H, Vallet-Pichard A, Equi-Andrade C et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 8537.
  • 173
    Kamar N, Rostaing L, Sandres-Saune K, Ribes D, Durand D, Izopet J. Amantadine therapy in renal transplant patients with hepatitis C virus infection. J. Clin. Virol. 2004; 30: 1104.
  • 174
    Calanca LN, Fehr T, Jochum W et al. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J. Clin. Virol. 2007; 39: 548.
  • 175
    Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am. J. Nephrol. 2001; 21: 43540.
  • 176
    Akyüz F, Beşişik F, Pinarbaşi B et al. The quality of life in hemodialysis patients with chronic hepatitis C virus infection. Turk. J. Gastroenterol. 2009; 20: 2436.
  • 177
    Dzekova P, Asani A, Selim G et al. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients. Int. J. Artif. Organs. 2009; 32: 1804.